Eliem Therapeutics, Inc.ELYMNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-39.48%
↑ 22% above average
Average (22q)
-50.30%
Historical baseline
Range
High:71.35%
Low:-568.75%
Volatility
-1272.5%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -39.48% |
| Q2 2025 | 53.61% |
| Q1 2025 | 63.21% |
| Q4 2024 | -433.33% |
| Q3 2024 | -148.93% |
| Q2 2024 | -56.84% |
| Q1 2024 | 41.33% |
| Q4 2023 | -2.42% |
| Q3 2023 | 25.51% |
| Q2 2023 | 71.35% |
| Q1 2023 | -145.32% |
| Q4 2022 | -9.21% |
| Q3 2022 | 36.15% |
| Q2 2022 | -4.33% |
| Q1 2022 | -22.69% |
| Q4 2021 | -14.07% |
| Q3 2021 | -7.76% |
| Q2 2021 | -26.57% |
| Q1 2021 | 54.46% |
| Q4 2020 | -568.75% |
| Q3 2020 | -40.49% |
| Q2 2020 | 17.58% |
| Q1 2020 | 0.00% |